In Europe, startups are catching up on “biogerontology” (science of aging) research, products and services and here is our sampling of five that are trying to make us live longer
Juvenescence is a UK biopharmaceutical company building a pipeline of therapeutic assets to target aging, regeneration and the diseases of aging. Juvenescence was founded by Jim Mellon, billionaire British businessman and philanthropist. Since its foundation in 2016, Juvenescence has raised €148 million with its most recent Series B round in August 2019, including €90 million with the participation of Mike Cannon-Brookes, the billionaire co-founder of Australian software giant Atlassian.
Juvenescence’s goal is to extend both lifespan and health-span, by developing therapeutics that slow aging and promote juvenescence (“the state or period of being young”). It partners with new companies that have longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Juvenescence’s pipeline companies tackle frontline, cutting-edge products like that of LyGenesis, whose technology will enable the use of a patient’s own lymph nodes as bioreactors to regrow functioning ectopic organs including liver, kidney, thymus, and pancreas. Another pipeline company is AgeX Therapeutics, a company applying intellectual property related to cell immortality and cell therapy.
Read More at EU Start Ups
Read the rest at EU Start Ups